AC Immune SA (ACIU)
2.36
-0.13
(-5.22%)
USD |
NASDAQ |
May 02, 16:00
2.36
0.00 (0.00%)
After-Hours: 19:59
AC Immune Cash from Operations (Quarterly): -17.21M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -17.21M |
| September 30, 2023 | -15.67M |
| June 30, 2023 | -16.26M |
| March 31, 2023 | -18.14M |
| December 31, 2022 | -18.99M |
| September 30, 2022 | -13.98M |
| June 30, 2022 | -19.11M |
| March 31, 2022 | -25.06M |
| December 31, 2021 | -19.74M |
| September 30, 2021 | -15.50M |
| June 30, 2021 | -17.46M |
| March 31, 2021 | -19.17M |
| December 31, 2020 | -19.82M |
| September 30, 2020 | -18.18M |
| June 30, 2020 | -15.47M |
| March 31, 2020 | -10.01M |
| December 31, 2019 | -13.40M |
| September 30, 2019 | 18.17M |
| Date | Value |
|---|---|
| June 30, 2019 | -15.42M |
| March 31, 2019 | 66.22M |
| December 31, 2018 | -12.21M |
| September 30, 2018 | -12.06M |
| June 30, 2018 | -6.718M |
| March 31, 2018 | -14.07M |
| December 31, 2017 | 7.130M |
| September 30, 2017 | -8.333M |
| June 30, 2017 | -9.393M |
| March 31, 2017 | -11.83M |
| December 31, 2016 | -7.035M |
| September 30, 2016 | 8.720M |
| June 30, 2016 | 0.3186M |
| March 31, 2016 | -7.736M |
| December 31, 2015 | -5.657M |
| September 30, 2015 | 34.42M |
| June 30, 2015 | -4.376M |
| March 31, 2015 | 21.42M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-25.06M
Minimum
Mar 2022
18.17M
Maximum
Sep 2019
-15.28M
Average
-17.21M
Median
Dec 2023
Cash from Operations (Quarterly) Benchmarks
| CRISPR Therapeutics AG | -96.07M |
| Addex Therapeutics Ltd | -0.5563M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -17.00M |
| MoonLake Immunotherapeutics | -12.34M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 25.14M |
| Cash from Financing (Quarterly) | 45.65M |
| Free Cash Flow | -68.17M |
| Free Cash Flow Per Share (Quarterly) | -0.2004 |
| Free Cash Flow to Equity (Quarterly) | -17.38M |
| Free Cash Flow to Firm (Quarterly) | -17.38M |
| Free Cash Flow Yield | -34.01% |